BioVie Inc.

NasdaqCM BIVI

BioVie Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

BioVie Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: BIVI

BioVie Inc.

CEO	Mr. Cuong Viet Do M.B.A.
IPO Date	Sept. 18, 2020
Location	United States
Headquarters	680 West Nye Lane
Employees	14
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Key trends

Past 5 years